Clinical Trials Browser

Unknown × OTHER_GOV × donafenib × Clear all

NCT05545124 2022-09-19

Study of Donafenib Combined With Tislelizumab in the Adjuvant Treatment of Primary HCC With High Risk of Recurrence

Phase 2 Unknown

Gastrointestinal

Carcinoma, Hepatocellular